title: The inhibition of mevalonate pathway induces upregulation of NALP3 expression: new insight in the pathogenesis of mevalonate kinase deficiency.
abstract: Mevalonate kinase deficiency (MKD) is a rare hereditary auto-inflammatory syndrome due to mutations in mevalonate kinase, the second enzyme of mevalonate pathway of cholesterol, and nonsterol-isoprenoids biosynthesis. The shortage of mevalonate-derived intermediates, and in particular of geranylgeranyl pyrophosphate (GGPP), has been linked with the activation of caspase-1 and thereby with the production of IL-1beta, but the true concatenation of these two events has not been clarified yet. We hypothesized that inflammasomes could mediate the activation of caspase-1 due to the shortage of GGPP. We monitored the expression of the principal proteins (NALP1, NALP3 and IPAF) of the three known inflammasomes, first in a cellular model of MKD and then in two MKD patients, after bacterial lipopolysaccharide (LPS) stimulation. In healthy subjects, alendronate alone induced the expression of NALP1 and NALP3, and then together with LPS it induced a dramatic increase in NALP3 expression. In MKD patients, NALP3 expression was higher than in untreated healthy controls. Our results, although preliminary, showed that the inhibition of the mevalonate pathway led to a hyper-expression of NALP3, suggesting a possible involvement of NALP3-inflammasome in the activation of caspase-1 consequent to GGPP decrement. This is the first time that the involvement of the inflammasome complexes was shown in MKD pathogenesis.
authors.affiliation: Medical Genetic Service, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy. pontillo@burlo.trieste.it
authors.forename: Alessandra
authors.initials: A
authors.lastname: Pontillo
authors.forename: Elisa
authors.initials: E
authors.lastname: Paoluzzi
authors.forename: Sergio
authors.initials: S
authors.lastname: Crovella
mesh_terms: D019386:Alendronate / Q000494:pharmacology; D002352:Carrier Proteins / Q000235:genetics* / Q000378:metabolism; D002648:Child; D005260:Female; D006801:Humans; D007249:Inflammation / Q000235:genetics / Q000473:pathology; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D053858:Metabolic Networks and Pathways / Q000187:drug effects; D054078:Mevalonate Kinase Deficiency / Q000209:etiology* / Q000235:genetics*; D008798:Mevalonic Acid / Q000378:metabolism*; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; D015854:Up-Regulation / Q000187:drug effects / Q000235:genetics*; D055815:Young Adult
chemical_list: D002352:Carrier Proteins; D008070:Lipopolysaccharides; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; C453881:NLRP3 protein, human; D008798:Mevalonic Acid; D019386:Alendronate